Latest Oncology News

Survival Benefit Found With Abiraterone/Prednisolone-Based Combos in High-Risk Nonmetastatic Prostate Cancer

Survival Benefit Found With Abiraterone/Prednisolone-Based Combos in High-Risk Nonmetastatic Prostate Cancer

September 19th 2021

Matthew Fowler

When added to androgen-deprivation therapy, abiraterone acetate and prednisolone with or without enzalutamide for 2 years improved survival outcomes in men with high-risk nonmetastatic prostate cancer.

Prednisone Added to ADT Plus Docetaxel Improves Radiographic PFS and OS in mCSPC

Prednisone Added to ADT Plus Docetaxel Improves Radiographic PFS and OS in mCSPC

September 19th 2021

Jamie Cesanek

Prednisone added to androgen-deprivation therapy plus docetaxel improved radiographic progression-free survival and overall survival in patients with de novo metastatic castration-sensitive prostate cancer.

Novel Therapy Appears Safe, Effective in Metastatic Castration Resistant Prostate Cancer

Novel Therapy Appears Safe, Effective in Metastatic Castration Resistant Prostate Cancer

September 19th 2021

Colleen Moretti

Sabizabulin was well tolerated and associated with significant and durable objective tumor responses in patients with metastatic castration resistant prostate cancer.

Nivolumab-Rucaparib Combo Induces Clinically Effective Outcomes in Subgroup of Patients with mCRPC

Nivolumab-Rucaparib Combo Induces Clinically Effective Outcomes in Subgroup of Patients with mCRPC

September 19th 2021

Ryan McDonald

A group of patients with metastatic castration resistant prostate cancer achieved favorable outcomes after receiving treatment with nivolumab in combination with rucaparib.

Switch to Darolutamide Maintenance Improves Survival in Taxane and NHA Pretreated mCRPC

Switch to Darolutamide Maintenance Improves Survival in Taxane and NHA Pretreated mCRPC

September 19th 2021

Nichole Tucker

Switching maintenance to darolutamide following taxane-based therapy with at least 1 novel hormonal agent showed statistically significant but clinically modest improvement in radiographic progression-free survival and event-free survival in patents with metastatic castration-resistant prostate cancer.

Latest Oncology Videos

All Oncology News

Dr. Palese on Emerging Technologies in Benign Prostatic Hyperplasia

September 10th 2021

Michael Palese, MD

Michael A. Palese, MD, discusses emerging technologies in benign prostatic hyperplasia.

Dr. Badani on Utilizing Multiport Robotic Retroperitoneal Partial Nephrectomies in RCC

September 10th 2021

Ketan K. Badani, MD

Ketan K. Badani, MD, discusses the utility of multiport robotic retroperitoneal partial nephrectomies in renal cell carcinoma (RCC).

Dr. Anderson on Updated KarMMa Data With Ide-Cel in Multiple Myeloma

September 10th 2021

Larry Anderson, MD, PhD

Larry Anderson, MD, PhD, discusses outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma, as demonstrated in the phase 2 KarMMa trial.

N-803/BCG Combo Shows Promising Responses, Tolerability in BCG-Unresponsive Bladder Cancer

September 10th 2021

Courtney Marabella

Bacille Calmette-Guérin (BCG) plus N-803 yielded promising responses and an encouraging safety profile in patients with BCG-unresponsive, non-muscle invasive bladder cancer carcinoma in situ.

Dr. Kahl on the Potential for Frontline BTK Inhibitor Combinations in MCL

September 10th 2021

Brad S. Kahl, MD

Brad S. Kahl, MD, discusses the potential utility of BTK inhibitor–based combinations in the frontline setting of mantle cell lymphoma.

RWE Demonstrates Robust PSA Response and Treatment Adherence of Apalutamide in CRPC

September 10th 2021

Jackie Collins

Patients with nonmetastatic castration-resistant prostate cancer demonstrated high adherence rates and favorable prostate-specific antigen response to apalutamide according to real-world evidence presented at the 2021 American Urological Association Annual Meeting.

Elevated Antibody Titers May Predict Nadofaragene Firadenovec Durability in BCG-Unresponsive NMIBC

September 10th 2021

Brittany Lovely

Antibody titers and fold changes may prove to be a prognostic marker for the efficacy of nadofaragene firadenovec for the treatment of patients with bacillus Calmette-Guérun unresponsive non-muscle invasive bladder cancer.

Atezolizumab plus Chemotherapy Displays Efficacy, Tolerability in NSCLC with Untreated Brain Metastases

September 10th 2021

Kyle Doherty

Atezolizumab plus carboplatin and pemetrexed yielded a favorable safety and efficacy profile in patients with advanced non-squamous non-small cell lung cancer with untreated brain metastases.

Elranatamab Alone or Plus Lenalidomide Shows Early Efficacy, Safety in Heavily Relapsed Myeloma

September 10th 2021

Kristi Rosa

Elranatamab elicited encouraging responses with a manageable toxicity profile when used alone or in combination with lenalidomide in patients with relapsed/refractory multiple myeloma, with efficacy observed even in those who received prior BCMA-directed therapy or who were triple-class refractory, according to data from the phase 1 MagnetisMM-1 trial.

CAR T-Cell Therapies Show Promise Across Indolent Lymphomas

September 10th 2021

Tony Berberabe, MPH

CAR T-cell products targeting CD19 are eliciting clinical activity in patients with indolent non-Hodgkin lymphoma, as seen in the ZUMA-5, SCHOLAR-5, and ELARA trials, but longer follow-up will showcase the true potential of this treatment in this subpopulation.

Rituximab-Bendamustine Combo Induces Superior Outcomes Over Other Regimens in Waldenström Macroglobulinemia

September 10th 2021

Ryan McDonald

Treatment with fixed-duration rituximab plus the chemotherapy bendamustine was associated with more favorable outcomes than the triplet of dexamethasone, rituximab, and cyclophosphamide, as well as bortezomib, dexamethasone, and rituximab in patients with treatment-naïve Waldenström macroglobulinemia.

BMI Is a Significant Predictor for Survival in mCRPC

September 10th 2021

Jason Harris

Obese men with metastatic castration-resistant prostate cancer have better disease-specific and overall survival than overweight or normal weight patients.

Cilta-Cel Continues to Yield Deep, Durable Response in Relapsed/Refractory Myeloma

September 10th 2021

Courtney Marabella

A single dose of ciltacabtagene autoleucel continued to elicit early, deep, and durable responses and showcase a manageable safety profile in heavily pretreated patients with multiple myeloma.

Cilta-Cel Emerges as Potential CAR T-Cell Option in Relapsed/Refractory Multiple Myeloma

September 10th 2021

Jamie Cesanek

The CAR T-cell therapy ciltacabtagene autoleucel has emerged as a potentially durable treatment strategy for patients with relapsed/refractory multiple myeloma who have progressed on 1 to 3 prior lines of treatment and are refractory to lenalidomide.

Dr. Martin on the Utility of Quadruplet-Based Regimens in Relapsed/Refractory Multiple Myeloma

September 10th 2021

Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Thomas G. Martin, MD, discusses the potential utility of quadruplet-based regimens in relapsed/refractory multiple myeloma.

See All News